blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1563068

EP1563068 - GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.03.2019
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  23.03.2018
FormerGrant of patent is intended
Status updated on  06.07.2017
FormerExamination is in progress
Status updated on  09.11.2016
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Astellas Pharma Inc.
5-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8411 / JP
[2018/30]
Former [2018/29]For all designated states
Ganymed Pharmaceuticals GmbH
An der Goldgrube 12
55131 Mainz / DE
Former [2015/23]For all designated states
Ganymed Pharmaceuticals AG
An der Goldgrube 12
55131 Mainz / DE
Former [2005/33]For all designated states
Ganymed Pharmaceuticals AG
Freiligrathstr. 12
55131 Mainz / DE
Inventor(s)01 / SAHIN, Ugur
Philipp von Zabern Platz 1
55116 Mainz / DE
02 / TÜRECI, Özlem
Philipp von Zabern Platz 1
55116 Mainz / DE
03 / KOSLOWSKI, Michael
Autogenstrasse 50
65933 Frankfurt / DE
 [2010/39]
Former [2007/12]01 / SAHIN, Ugur
Philipp von Zabern Platz 1
55116 Mainz / DE
02 / TÜRECI, Özlem
Philipp von Zabern Platz 1
55116 Mainz / DE
03 / KOSLOWSKI, Michael
Kaiserstrasse 72
55116 Mainz / DE
Former [2005/33]01 / SAHIN, Ugur
Philipp von Zabern Platz 1
55116 Mainz / DE
02 / TÜRECI, Özlem
Philipp von Zabern Platz 1
55116 Mainz / DE
03 / KOSLOWSKI, Michael
Rodderweg 24
50999 Köln / DE
Representative(s)Schnappauf, Georg, et al
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2018/17]
Former [2005/33]Schnappauf, Georg Dr., et al
Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6
81679 München / DE
Application number, filing date03773719.421.11.2003
[2005/33]
WO2003EP13091
Priority number, dateDE2002105460122.11.2002         Original published format: DE 10254601
[2005/33]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report
No.:WO2004047863
Date:10.06.2004
Language:DE
[2004/24]
Type: A2 Application without search report 
No.:EP1563068
Date:17.08.2005
Language:DE
The application published by WIPO in one of the EPO official languages on 10.06.2004 takes the place of the publication of the European patent application.
[2005/33]
Type: B1 Patent specification 
No.:EP1563068
Date:25.04.2018
Language:DE
[2018/17]
Search report(s)International search report - published on:EP06.01.2005
ClassificationIPC:C07K16/18, C07K16/30, G01N33/574, A61K39/395, C07K14/47
[2015/51]
CPC:
C07K14/47 (EP,CN,KR,US); A61K39/39558 (KR); A61K48/005 (CN);
C07K16/3076 (US); A61K39/0011 (CN); A61K39/395 (CN);
A61K47/549 (US); A61P1/04 (EP); A61P1/18 (EP);
A61P11/00 (EP); A61P13/08 (EP); A61P13/12 (EP);
A61P15/00 (EP); A61P17/00 (EP); A61P35/00 (EP,KR);
A61P43/00 (EP); C07K16/18 (EP,CN,KR,US); C07K16/30 (EP,KR,US);
C07K16/3023 (EP,US); C07K16/3046 (EP,US); C12Q1/6886 (CN);
G01N33/5011 (CN); G01N33/5017 (CN); G01N33/57407 (CN);
G01N33/57484 (EP,CN,US); A61K2039/505 (EP,KR,US); C07K2317/30 (KR,US);
C07K2317/34 (EP,KR,US); C12N2503/02 (CN); C12Q2600/136 (CN);
C12Q2600/158 (CN); G01N2500/10 (CN) (-)
Former IPC [2005/33]C12N15/11
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2018/17]
Former [2005/33]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL28.04.2005
LT28.04.2005
LV28.04.2005
MK28.04.2005
TitleGerman:IN TUMOREN DIFFERENTIELL EXPRIMIERTE GENPRODUKTE UND DEREN VERWENDUNG[2005/33]
English:GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF[2005/33]
French:PRODUITS GENIQUES EXPRIMES DE MANIERE DIFFERENTIELLE DANS DES TUMEURS ET LEUR UTILISATION[2005/33]
Entry into regional phase28.04.2005National basic fee paid 
28.04.2005Designation fee(s) paid 
28.04.2005Examination fee paid 
Examination procedure28.04.2005Examination requested  [2005/33]
29.07.2005Amendment by applicant (claims and/or description)
08.09.2009Despatch of a communication from the examining division (Time limit: M04)
08.09.2009Invitation to provide information on prior art
18.01.2010Reply to a communication from the examining division
18.01.2010Reply to the invitation to provide information on prior art
09.03.2012Despatch of a communication from the examining division (Time limit: M06)
06.09.2012Reply to a communication from the examining division
07.10.2013Despatch of a communication from the examining division (Time limit: M06)
10.04.2014Reply to a communication from the examining division
09.11.2015Cancellation of oral proceeding that was planned for 11.11.2015
11.11.2015Date of oral proceedings (cancelled)
04.01.2016Communication of intention to grant the patent
02.02.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.03.2016Communication of intention to grant the patent
27.10.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.06.2017Date of oral proceedings
06.07.2017Minutes of oral proceedings despatched
07.07.2017Communication of intention to grant the patent
03.01.2018Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
13.03.2018Fee for grant paid
13.03.2018Fee for publishing/printing paid
13.03.2018Receipt of the translation of the claim(s)
Divisional application(s)EP11007306.1  / EP2399995
EP11007307.9  / EP2399996
EP11007308.7  / EP2399997
EP11007309.5  / EP2399998
EP11007310.3  / EP2399999
EP11007311.1  / EP2400000
EP11007312.9  / EP2400001
EP11007313.7  / EP2400002
EP11007314.5  / EP2400003
EP11007315.2  / EP2400004
EP11007316.0  / EP2400005
EP11007317.8  / EP2400006
EP11007318.6  / EP2400007
EP11007319.4  / EP2400008
EP11007320.2  / EP2400009
EP11007321.0  / EP2400010
EP11007322.8  / EP2400011
EP11007323.6  / EP2400012
EP11007324.4  / EP2400013
EP11007325.1  / EP2400014
EP11007326.9  / EP2400015
EP11007327.7  / EP2400016
EP11007328.5  / EP2400017
EP11007329.3  / EP2400018
EP11007330.1  / EP2400019
EP18157559.8  / EP3348570
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.09.2009
Opposition(s)28.01.2019No opposition filed within time limit [2019/14]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
13.03.2018Request for further processing filed
13.03.2018Full payment received (date of receipt of payment)
Request granted
26.03.2018Decision despatched
The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
27.10.2016Request for further processing filed
27.10.2016Full payment received (date of receipt of payment)
Request granted
10.11.2016Decision despatched
Fees paidRenewal fee
14.11.2005Renewal fee patent year 03
14.11.2006Renewal fee patent year 04
30.11.2007Renewal fee patent year 05
31.10.2008Renewal fee patent year 06
27.10.2009Renewal fee patent year 07
25.11.2010Renewal fee patent year 08
28.11.2011Renewal fee patent year 09
28.11.2012Renewal fee patent year 10
29.11.2013Renewal fee patent year 11
27.11.2014Renewal fee patent year 12
27.11.2015Renewal fee patent year 13
29.11.2016Renewal fee patent year 14
30.11.2017Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.11.2003
CY25.04.2018
CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
TR25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
AT21.11.2018
IE21.11.2018
LU21.11.2018
BE30.11.2018
[2020/32]
Former [2020/30]HU21.11.2003
CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
TR25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
AT21.11.2018
IE21.11.2018
LU21.11.2018
BE30.11.2018
Former [2020/16]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
TR25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
AT21.11.2018
IE21.11.2018
LU21.11.2018
BE30.11.2018
Former [2020/11]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
AT21.11.2018
IE21.11.2018
LU21.11.2018
BE30.11.2018
Former [2019/51]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
IE21.11.2018
LU21.11.2018
BE30.11.2018
Former [2019/48]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
IE21.11.2018
LU21.11.2018
Former [2019/34]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
LU21.11.2018
Former [2019/33]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
MC25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
Former [2019/26]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SI25.04.2018
SK25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
Former [2019/10]CZ25.04.2018
DK25.04.2018
EE25.04.2018
FI25.04.2018
NL25.04.2018
RO25.04.2018
SE25.04.2018
SK25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
Former [2019/09]DK25.04.2018
EE25.04.2018
FI25.04.2018
NL25.04.2018
SE25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
Former [2019/08]DK25.04.2018
FI25.04.2018
NL25.04.2018
SE25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
Former [2019/03]FI25.04.2018
NL25.04.2018
SE25.04.2018
BG25.07.2018
GR26.07.2018
PT27.08.2018
Former [2018/52]FI25.04.2018
NL25.04.2018
SE25.04.2018
BG25.07.2018
GR26.07.2018
Former [2018/49]FI25.04.2018
NL25.04.2018
SE25.04.2018
BG25.07.2018
Former [2018/47]FI25.04.2018
NL25.04.2018
Former [2018/43]NL25.04.2018
Cited inInternational search[XY]WO9964452  (SMITHKLINE BEECHAM CORP [US]) [X] 1-5,7-16,20-22,24-27,29,32-35,37-39,44,47-50,53,55-60,64,66,74-81,83,84,86-89,95,98 * the whole document * [Y] 1-72,74-81,83-98;
 [Y]WO0127257  (UNIV ARKANSAS [US]) [Y] 1-72,74-81,83-98 * the whole document *;
 [X]US6235481  (HORIKAWA YUKIO [JP], et al) [X] 74,80,81,83-85 * column 79, paragraph L - column 80, paragraph 1; example 4 *;
 [Y]WO0162920  (CORIXA CORP [US]) [Y] 1-72,74-81,83-98 * the whole document *;
 [Y]WO0175067  (HYSEQ INC [US], et al) [Y] 1-72,86-98 * abstract *;
 [XY]WO0214500  (CHIRON CORP [US], et al) [X] 1-5,7-16,20-27,29-39,44,47-50,53,55-60,64,66,71,72,86-89,95,98 * abstract * * page 267 * * page 409 * * page 486 * * page 505 * * page 614 * * page 646 * * page 661 * * page 680 * * page 684 * [Y] 1-72,86-98,1-72,86-98;
 [X]WO02061087  (LIFESPAN BIOSCIENCES INC [US], et al) [X] 74,75,83,84 * paragraph [0129] *;
 [PX]WO02103028  (BIOMEDICAL CT [RU]) [PX] 74 * page 41, paragraph 8 *;
 [Y]  - BARANOVA^A A V ET AL, "In silico screening for tumour-specific expressed sequences in human genome", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20011109), vol. 508, no. 1, ISSN 0014-5793, pages 143 - 148, XP004322294 [Y] 1-72,74-81,83-98 * page 147, column L * * page 146, column R, paragraph L * * table 3 *

DOI:   http://dx.doi.org/10.1016/S0014-5793(01)03028-9
 [Y]  - REITER Y ET AL, "peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, (199704), vol. 94, ISSN 0027-8424, pages 4631 - 4636, XP002967291 [Y] 90-94 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.94.9.4631
 [A]  - O'DOWD B F ET AL, "Discovery of Three Novel G-Protein-Coupled Receptor Genes", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, (19980115), vol. 47, no. 2, ISSN 0888-7543, pages 310 - 313, XP004449298 [A] 1-98 * page 312, column L, paragraph 1 *

DOI:   http://dx.doi.org/10.1006/geno.1998.5095
 [Y]  - ENGBERG J ET AL, "RECOMBINANT ANTIBODIES WITH THE ANTIGEN-SPECIFIC, MHC RESTRICTED SPECIFICITY OF T CELLS: NOVEL REAGENTS FOR BASIC AND CLINICAL INVESTIGATIONS AND IMMUNOTHERAPY", IMMUNOTECHNOLOGY, XX, XX, (199903), vol. 4, pages 273 - 278, XP000991083 [Y] 90-94 * abstract *

DOI:   http://dx.doi.org/10.1016/S1380-2933(98)00017-7
 [A]  - KOSLOWSKI MICHAEL ET AL, "Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer", CANCER RESEARCH, (20021115), vol. 62, no. 22, ISSN 0008-5472, pages 6750 - 6755, XP002284383 [A] 1-72,74-81,83-98 * abstract *
ExaminationWO0154708
 US2002119130
    - RIEMER A B ET AL, "Matching of trastuzumab (Herceptin<(>R)) epitope mimics onto the surface of Her-2/neu - a new method of epitope definition", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 42, no. 9, ISSN 0161-5890, (20050501), pages 1121 - 1124, (20050501), XP027635008
    - SAHIN UGUR ET AL, "Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20081201), vol. 14, no. 23, doi:10.1158/1078-0432.CCR-08-1547, ISSN 1078-0432, pages 7624 - 7634, XP002588324

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-08-1547
    - Y Sanada ET AL, "Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype", The Journal of Pathology, (20060401), vol. 208, no. 5, doi:10.1002/path.1922, ISSN 0022-3417, pages 633 - 642, XP055080460

DOI:   http://dx.doi.org/10.1002/path.1922
    - P Büchler ET AL, "Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)", Journal of Gastrointestinal Surgery, (20010401), vol. 5, no. 2, doi:10.1016/S1091-255X(01)80025-1, ISSN 1091-255X, pages 139 - 146, XP055188573

DOI:   http://dx.doi.org/10.1016/S1091-255X(01)80025-1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.